Polomar Health Services, Inc. filings document a Nevada health-services operating company with disclosures centered on pharmaceutical product fulfillment and distribution arrangements. Form 8-K reports cover material definitive agreements, amendments and termination-related notices involving the marketing of the company's pharmaceutical products, prescription fulfillment responsibilities and related account-management services.
Registration statements and amendments describe securities registration activity, historical financial statements and capital-structure disclosures. Late-filing notices address annual and quarterly reporting timing, while periodic disclosure categories include operating and financial results and other corporate events reported under the Exchange Act.
Polomar Health Services is moving its merger with Altanine forward by waiving several closing conditions in their Merger Agreement. These include prior requirements for S-4 effectiveness, Nasdaq listing approval, a minimum $25 million Equity Credit Line, a reverse stock split to $10.00 per share, and completion of a concurrent financing.
The parties also amended Section 6.2(e) so Polomar will deliver audited financial statements for the years ended December 31, 2025 and December 31, 2024, prepared under U.S. GAAP by a PCAOB-registered firm and suitable for SEC filings.
Separately, CEO Terrence M. Tierney agreed that, upon closing of the merger, he will step down as CEO, President and Secretary and become Executive Vice President and Chief Operating Officer. His base salary is retroactively set at $19,000 per month from November 1, 2025, with a possible $5,000 monthly increase if certain requirements are met. His annual bonus becomes discretionary and tied to key performance indicators, he receives 500,000 additional nonqualified stock options, and severance for termination without cause or for good reason becomes four months of base salary plus a pro-rata share of the prior year’s bonus.
Polomar also consents to Altanine granting a security interest over all assets of its subsidiary Pinata Holdings and all Altanine assets, including deposit accounts, to CWR 1, LLC, an affiliate of both Polomar and Altanine, in connection with a modified note.
Polomar Health Services, Inc. files its annual report describing a development-stage specialty compounding pharmacy focused on GLP-1 weight-loss drugs, erectile dysfunction treatments and future inhaled formulations. The company reports substantial operating losses, limited operating history and insufficient capital, raising doubt about its ability to continue as a going concern.
Polomar relies on telehealth partners and its own planned SlimRx online platform, with key product launches pushed into late 2026 and a major marketing partner suspending sales and seeking to terminate a distribution agreement. A planned merger with Altanine would shift roughly 80% of future equity to Altanine holders and further dilute existing shareholders.
Polomar Health Services, Inc. notifies the SEC it will file its Annual Report on Form 10-K late for the fiscal year ended December 31, 2025. The company says it was unable, without unreasonable effort or expense, to timely compile all required disclosures and expects to file within the 15-calendar-day extension following the prescribed due date.
Polomar reports revenues of $648,321 for the twelve months ended December 31, 2025, up from $58,824 for the prior year. Operating expenses rose to approximately $2,206,920 and the company recorded a net loss of approximately $1,941,860 for the year, compared with a net loss of $1,305,962 the prior year. Management attributes revenue growth to increased prescription fulfillment and higher expenses to legal, audit, payroll, consulting and interest costs.
Polomar Health Services, Inc. informs stockholders that holders representing approximately 65% of voting capital and the board approved, by written consent, a package of corporate actions including amendments to opt out of certain Nevada anti-takeover statutes, a proposed Merger with Altanine Inc., a reverse stock split (1-for-2 to 1-for-100 range), an increase in authorized common shares to 425,000,000, and approval to establish an equity line of credit up to $25,000,000. The actions were approved on September 8, 2025 and January 30, 2026 and furnished in an Information Statement dated March 12, 2026. Closing of the Merger remains subject to customary conditions including a PCAOB-compliant audit for Altanine, an effective Form S-4 registration statement, Nasdaq listing approval, certain shareholder consents, and effecting a reverse split to achieve a $10.00 per share target prior to closing.
Polomar Health Services Inc. has obtained written consent from holders of about 65% of its voting common stock to approve six major actions without a stockholder meeting. These include opting out of certain Nevada anti‑takeover statutes, a reverse merger with Altanine Inc., a reverse stock split, an increase in authorized shares and approval for a large equity financing facility.
Under the Altanine merger, Altanine will become a wholly owned subsidiary and its stockholders are expected to own roughly 80% of the combined company’s common stock, with current Polomar holders owning about 20%. The company may implement a reverse stock split between 1‑for‑2 and 1‑for‑100 and raise up to $25 million through an equity line of credit, while increasing authorized common shares from 295,000,000 to 425,000,000.
Polomar Health Services Inc. has obtained written consents from holders of about 65% of its voting stock to approve major corporate changes without a shareholder meeting. These include a planned merger with Altanine Inc., a potential reverse stock split, and a large authorized share increase.
Under the Merger Agreement, Altanine will merge into a Polomar subsidiary, and Altanine shareholders are expected to own about 80% of the combined company’s common stock, leaving current Polomar holders with about 20%. Board control and senior management will shift to Altanine’s nominees after closing.
Stockholders also approved opting out of Nevada anti‑takeover statutes, a reverse stock split in a range from 1‑for‑2 to 1‑for‑100, an increase in authorized common shares from 295,000,000 to 425,000,000, and the ability to establish an equity line of credit of up to $25 million that could lead to significant future share issuance.
Polomar Health Services, Inc. has registered up to 7,710,219 shares of common stock for resale by existing stockholders. The company will not receive any proceeds from these sales; all proceeds go to the selling stockholders, who may sell at a fixed price of $0.20 per share until any national exchange or OTCQX/OTCQQB listing, and thereafter at market prices. As of December 11, 2025, 28,053,090 shares of common stock were outstanding, and the stock last closed at $0.08 on the OTCID Basic Market.
Polomar operates a Florida-licensed specialty compounding pharmacy, focusing on dermatology, GLP‑1 weight loss drugs and men’s health, and holds a license to patent‑pending inhalable formulations such as sildenafil. It is a development-stage business with a history of losses, significant related‑party debt and substantial doubt about its ability to continue as a going concern without new financing. A pending merger with Altanine Inc. is expected, if completed, to leave Altanine holders owning about 80% of the combined company, subject to numerous conditions including a Nasdaq listing and a reverse stock split.
Polomar Health Services, Inc. disclosed a second amendment to its Amended and Restated Product Fulfillment and Distribution Agreement with ForHumanity, Inc. and Island Group 40, LLC. The initial exclusivity period is pushed back from March 31, 2025 to June 30, 2025, giving more time under the existing exclusive arrangement.
The Company gains a new right to terminate the agreement if specified minimum average monthly sales targets are not met between January 1, 2026 and July 31, 2026. Exclusivity can be extended through December 31, 2026 if the Company receives at least $1,750,000 in revenues from ForHumanity on or before June 30, 2026, and further through June 30, 2027 if total revenues from ForHumanity reach $5,000,000 for the calendar year ending December 31, 2026.
The payment schedule for remaining guaranteed amounts is revised to $100,000 on or before December 8, 2025, $200,000 on or before December 29, 2025, and $200,000 on or before January 12, 2026. Polomar notes it has already received $350,000 of the total $750,000 in guaranteed payments tied to this agreement.